References
1. Moise Jr. K.J., Argoti P.S. Management and prevention of red cell
alloimmunization in pregnancy: a systematic review. Obstet Gynecol,
2012. 120 (5): p. 1132-9.
2. Geaghan S.M. Diagnostic laboratory technologies for the fetus and
neonate with isoimmunization. Semin Perinatol, 2011. 35 (3): p.
148-54.
3. Delaney, M., Matthews D.C. Hemolytic disease of the fetus and
newborn: managing the mother, fetus, and newborn. Hematology Am Soc
Hematol Educ Program, 2015. 2015 : p. 146-51.
4. Murray, N.A., Roberts I.A.G. Haemolytic disease of the newborn. Arch
Dis Child Fetal Neonatal Ed, 2007. 92 (2): p. F83-8.
5. Smitherman H., Stark A.R., Bhutani V.K. Early recognition of neonatal
hyperbilirubinemia and its emergent management. Semin Fetal Neonatal
Med, 2006. 11 (3): p. 214-24.
6. Bhat Y.R., Kumar C.G.P. Morbidity of ABO haemolytic disease in the
newborn. Paediatr Int Child Health, 2012. 32 (2): p. 93-6.
7. Kumar R., Saini N., Kaur P., Sood T., Kaur P., Bedi R.K., et al.
Severe ABO Hemolytic Disease of Newborn with High Maternal Antibody
Titres in a Direct Antiglobulin Test Negative Neonate. Indian J Pediatr,
2016. 83 (7): p. 740-1.
8. Metcalf R.A., Khan J., Andrews J., Mayock D., Billimoria Z., Pagano
M.B., et al. Severe ABO Hemolytic Disease of the Newborn Requiring
Exchange Transfusion. J Pediatr Hematol Oncol, 2019. 41 (8): p.
632-634.
9. Burgos A.E., Schmitt S.K., Stevenson D.K., Phibbs C.S. Readmission
for neonatal jaundice in California, 1991-2000: trends and implications.
Pediatrics, 2008. 121 (4): p. e864-9.
10. Maisels M.J., Kring E. Length of stay, jaundice, and hospital
readmission. Pediatrics, 1998. 101 (6): p. 995-8.
11. Sgro M., Campbell D., Shah V. Incidence and causes of severe
neonatal hyperbilirubinemia in Canada. CMAJ, 2006. 175 (6): p.
587-90.
12. Matteocci A., Rosa A.D., Buffone E., Pierelli L. Retrospective
analysis of HDFN due to ABO incompatibility in a single institution over
6 years. Transfus Med, 2019. 29 (3): p. 197-201.
13. Akanmu A.S., Oyedeji O.A., Adeyemo T.A., Ogbenna A.A. Estimating the
Risk of ABO Hemolytic Disease of the Newborn in Lagos. J Blood Transfus,
2015. 2015 : p. 560738.
14. Newman T.B., Xiong B., Gonzales V.M., Escobar G.J. Prediction and
prevention of extreme neonatal hyperbilirubinemia in a mature health
maintenance organization. Arch Pediatr Adolesc Med, 2000.154 (11): p. 1140-7.
15. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia.
Management of hyperbilirubinemia in the newborn infant 35 or more weeks
of gestation. Pediatrics, 2004. 114 (1): p. 297-316.
16. Han P., Kiruba R., Ong R., Joseph R., Tan K.L., Wong H.B.
Haematolytic disease due to ABO incompatibility: incidence and value of
screening in an Asian population. Aust Paediatr J, 1988. 24 (1):
p. 35-8.
17. Van Rossum H.H., De Kraa N., Thomas M., Holleboom C.A.G., Castel A.,
Van Rossum A.P. Comparison of the direct antiglobulin test and the
eluate technique for diagnosing haemolytic disease of the newborn.
Practical Laboratory Medicine, 2015. 3 : p. 17-22.
18. Izetbegovic S. Occurrence of ABO And RhD Incompatibility with Rh
Negative Mothers. Mater Sociomed, 2013. 25 (4): p. 255-8.
19. Einarsdottir H., Ji Y., Visser R., Chunyan M., Guangping L.,
Scherjon S. H435-containing immunoglobulin G3 allotypes are transported
efficiently across the human placenta: implications for
alloantibody-mediated diseases of the newborn. Transfusion, 2014.54 (3): p. 665-71.
20. Bakkeheim E., Bergerud U., Schmidt-Melbye AC., Akkök C.A., Liestøl
K., Fugelseth D. Maternal IgG anti-A and anti-B titres predict outcome
in ABO-incompatibility in the neonate. Acta Paediatr, 2009.98 (12): p. 1896-901.
21. Valsami S., Politou M., Boutsikou T., Briana D., Papatesta M.,
Malamitsi-Puchner A. Importance of Direct Antiglobulin Test (DAT) in
Cord Blood: Causes of DAT (+) in a Cohort Study. Pediatr Neonatol, 2015.56 (4): p. 256-60.
22. Kaplan M., Hammerman C., Vreman H.J., Wong R.J., Stevenson D.K.
Hemolysis and hyperbilirubinemia in antiglobulin positive, direct ABO
blood group heterospecific neonates. J Pediatr, 2010. 157 (5):
p. 772-7.
23. Garratty G., Glynn S.A., McEntire R. ABO and Rh(D) phenotype
frequencies of different racial/ethnic groups in the United States.
Transfusion, 2004. 44 (5): p. 703-6.
24. Bhutani V.K., Johnson L., Sivieri E.M. Predictive ability of a
predischarge hour-specific serum bilirubin for subsequent significant
hyperbilirubinemia in healthy term and near-term newborns. Pediatrics,
1999. 103 (1): p. 6-14.
25. Christensen R.D., Baer V.L., MacQueen B.C., O’Brien E.A., Ilstrup
S.J. ABO hemolytic disease of the fetus and newborn: thirteen years of
data after implementing a universal bilirubin screening and management
program. J Perinatol, 2018. 38 (5): p. 517-525.